About Us

Who We Are

The Johns Hopkins University Baltimore-India Clinical Trials Unit (JHUBI-CTU) is a collaboration and integration of 2 Clinical Research Sites (CRS’s):
 

The CTU supports clinical studies offered by 3 NIAID Clinical Research Networks

  1. AIDS Clinical Trials Group (ACTG)
  2. HIV Prevention Trials Network (HPTN)
  3. International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)

The JHUBI-CTU works with patients at high risk for HIV and Hepatitis C in Baltimore and at one of the largest HIV/infectious diseases clinical care and clinical research units on the Indian subcontinent.

The CTU includes a highly experienced international leadership that is also uniquely positioned to make significant and strategic scientific contributions. 
 

Three Specific Aims

  1. Science. The CTU’s innovative Scientific Coordinating Committees bring together expertise in our strongest fields: Tuberculosis, Hepatitis, HIV Cure, HIV Prevention, Clinical Pharmacology, Pediatric & Adolescent Research, Inflammation & End-Organ Complications, Antibiotic Resistance, and Training & Mentorship.

    The Committees are highly creative in developing new study proposals, identifying and prioritizing studies for site implementation, and encouraging young and international investigators to contribute to novel scientific concepts valued by the networks we support.

  2. Populations. Our sites work with important and often under-represented populations.

    1. Impoverished urban African-Americans and other communities of color, those with a history of intravenous drug use and substance abuse in Baltimore 
    2. Vulnerable sexually active young urban MSM and women in Baltimore 
    3. Pregnant women, adolescents, and adults in urban India.


    Because both sites provide top-quality clinical care and clinical research at the same facility, we can efficiently identify potential research participants and rapidly enroll them into high priority research using our integrated clinical care and clinical research teams.

  3. Management. Our efficient and highly integrated administrative structure facilitates high quality clinical research while taking advantage of shared resources, investigator expertise and synergies among sites.

Clinical Trials

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

Identification of Biomarkers That Can Predict Progression...

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort...

Read More

IMPAACT 2034 - Phase I Study of the Pharmacokinetics,...

This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More